Monday, July 27, 2015 Last update: 10:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

The Best of U.S. Company Tech News - Updated Daily

Wednesday, May 16, 2012

  • Posted at 9:16 PM
    J2 Global Communications, Inc., has entered into a patent license agreement with Klausner Technologies, Inc., under Klausner Technologies’ visual voicemail patents, for J2 Global’s consumer and enterprise visual voicemail products. J2 Global is the 49th company to license Klausner ... read more
  • Posted at 9:16 PM
    Earthlink, Inc., AireSpring, Inc., Bandwith.com, Inc. and Nextiva, Inc. have each entered into separate patent license agreements with Klausner Technologies, Inc., under Klausner Technologies’ U.S. Visual Voicemail patents, for their consumer and enterprise visual voicemail products. The four companies ... read more
  • Posted at 9:15 PM
    Samsung Electronics Co., Ltd (KS:005930) has just entered into a patent license agreement with Klausner Technologies, Inc., under the Klausner U.S. and international Visual Voicemail patents. About Klausner Technologies, Inc.: Klausner Technologies was founded by Judah Klausner, inventor of ... read more
  • Posted at 9:02 PM
    IBM (NYSE: IBM) today announced it is helping improve healthcare delivery in Haiti through its collaboration with 'Colleagues In Care' Global Health Network. (Photo: http://photos.prnewswire.com/prnh/20120517/NY08579-INFO)(Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO) The organization is using IBM cloud-based social analytics and collaboration services to provide the global network of healthcare volunteers with immediate access to critical data and information for the current healthcare needs of the Haitian citizens. The network consists of approximately 200 doctors, nurses, and business professionals coming together virtually from all around the globe ... read more
  • Posted at 9:00 PM
    F5 Networks, Inc. (NASDAQ:FFIV), the global leader in Application Delivery Networking (ADN), today announced that it will participate in several conference sessions and host a booth as a Bronze sponsor of the LTE World Summit 2012, taking place May 22–24 ... read more
  • Posted at 9:00 PM
    Sony's a NEX-F3 digital camera delivers professional quality photos with a compact, pocket-sized body, allowing consumers to explore the creative world of high-quality, interchangeable lens photography in a refreshingly fun and entertaining way. The new NEX-F3 camera features the same space-saving mirrorless design as other models in Sony's E-mount family as well as an advanced, 16.1 effective megapixel Exmor(TM) APS HD CMOS sensor, identical in size to sensors found in traditional DSLR cameras. The large sensor takes in ... read more
  • Posted at 9:00 PM
    Lightweight, easy to use and packed with a variety of useful features, the new Sony SLT-A37 camera is an ideal choice for consumers eager to explore the world of interchangeable lens DSLR photography. The new a37 camera is the latest to feature Sony's acclaimed Translucent Mirror Technology, which delivers a potent combination of fast shooting, non-stop phase detection autofocus and continuous live image preview during still and full HD video (60i/24p) shooting. This innovative technology also allows the new a37 ... read more
  • Posted at 4:29 PM
    Traackr, Inc., the web's leading influencer discovery platform, welcomes to its advisory board Andrea “Andy” Cunningham, president of Bite Communications North America, and founder and president of Series C. Andy Cunningham, president of Bite Communications, has been named to the Traackr advisory board. (Photo: Business Wire) ... read more
  • Posted at 3:45 PM
    Vidable, Inc. (Other-OTC: VIBE.PK) (the "Company"), today announced the launch of a new marketing campaign under which they will offer incentive credits, or coupons on their website, which can be applied against the cost of certain pay-services on the Vidable website. This campaign is in response to a recent BIA/Kelsey report under which small and medium businesses (SMBs) surveyed reported they plan to allocate 26 percent of their advertising budgets to digital/online media over the next 12 months. Management ... read more
  • Posted at 3:26 PM
    Visionet Systems announces it has established a processing center in Pittsburgh, PA. Visionet’s Pittsburgh office delivers software and business process outsourcing services to the financial services industry. The new office will preliminary offer Title Services, Recording, Pre/Post Close Loan Audits, Loan QA/QC Services, HUD Prep, Curative ... read more
  • Posted at 3:24 PM
    Attensity, the leading provider of social analytics and engagement applications, today announced the results of its analysis of public reaction in social media to the new Facebook Timeline format for profile pages. Using Attensity Analyze, the company's social analytics application, Attensity processed 138,572 public comments posted on Facebook, Twitter and blogs over a six-week period. The results, showing an overwhelming 93 percent of comments contain negative sentiment toward Timeline, are published on the Attensity blog at blog.attensity.com/?p=4545. (Photo: http://photos.prnewswire.com/prnh/20120516/SF08998) ... read more
  • Posted at 3:16 PM
    ClearOne (NASDAQ: CLRO) today announced the company's Board of Directors has approved a stock repurchase program. Under the program, ClearOne is authorized to repurchase up to $2 million of its outstanding shares of common stock from time to time over the next 12 months in open market or privately negotiated transactions depending on prevailing market conditions and other factors. The repurchase program may be suspended or discontinued at any time. All purchases will be executed in accordance with applicable ... read more
  • Posted at 3:08 PM
    Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. A summary of ... read more
  • Posted at 3:05 PM
    Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the results of a retrospective subpopulation analysis of 183 patients with cancer from the company's two large Phase 3 trials, which showed the cancer patients with Clostridium difficile-associated diarrhea (CDAD) who were treated with DIFICID® (fidaxomicin) tablets experienced resolution of their diarrheal symptoms approximately two days faster than those treated with oral vancomycin. These results will be presented on June 2nd at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in ... read more
  • Posted at 3:04 PM
    CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of Hemosphere, Inc. Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. CryoLife will begin the integration of the Hemosphere business immediately and expects to begin training its sales force on the HeRO Graft in ... read more
  • Posted at 3:02 PM
    Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study. Blinatumomab is the first of a new class of agents called bi-specific T cell engagers (BiTE®) antibodies, designed to harness the body's cell-destroying T cells to kill cancer cells. Blinatumomab targets cells expressing CD19, ... read more
  • Posted at 3:01 PM
    Amgen (NASDAQ: AMGN) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with rilotumumab in combination with chemotherapy improved median overall survival (OS) in patients whose tumors exhibited high MET protein expression. Full results of the study will be presented in an ... read more
  • Posted at 3:00 PM
    SRI Sarnoff's Iris on the Move® N-Glance(TM) identification system has received Lenel factory certification for its interface to Lenel's OnGuard® software system. SRI is now a member of the Lenel OpenAccess Alliance Program. This certification validates SRI's IOM N-Glance as a biometric product for Lenel access control systems. "SRI Sarnoff has completed the required factory testing at Lenel to validate the functionality of its interface to OnGuard," said Gidon Lissai, director of strategic alliances, Lenel. "We look forward to their ... read more
  • Posted at 3:00 PM
    McLane Advanced Technologies (MAT), a global provider of Information Technology and logistics solutions, is pleased to announce that Command Sergeant Major (Retired) Daniel K. Elder is now a Hall of Famer in the US Army Ordnance Corps. Mr. Elder, Senior Director of Business Development at MAT, has 26 years of vast military leadership, with 11 years' experience as a Command Sergeant Major. "We are extremely proud of Dan Elder," said McLane Advanced Technologies Vice President John Ballantyne. "His values and ... read more
  • Posted at 3:00 PM
    A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial (Photo: http://photos.prnewswire.com/prnh/20120516/MM07672 ) A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by ... read more